Adam M. Burgoyne

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott et al. · Journal of the National Comprehensive Cancer Network · 2021 · 999 citations · Full text

Surgical Oncology, Cancer Management, Pathology +22

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu, Alexander R. Abbas, Marina Ruiz de Galarreta et al. · Nature Medicine · 2022 · 580 citations

Medicine, Immunology, Molecular Correlates +9

FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors

Eileen Shi, Juliann Chmielecki, Chih‐Min Tang et al. · Journal of Translational Medicine · 2016 · 218 citations · Full text

NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023

Al B. Benson, Michael I. D’Angelica, Thomas A. Abrams et al. · Journal of the National Comprehensive Cancer Network · 2023 · 184 citations · Full text

Nccn Guidelines® Insights, Molecular Testing, Surgical Oncology +22